[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"drug-sensitive-test-in-vitro\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:drug-sensitive-test-in-vitro":62},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100568880",false,"NCT06686979","PDO Based Drug Sensitive Test in R\u002FM SGC","Consistency Evaluation of Drug Efficacy Between Clinical Systemic Treatment and Drug Sensitive Test Based on Patient-derived Organoid in Patients With Recurrent\u002FMetastatic Salivary Gland Cancer: A Prospective, Multicenter, Observational Study","Inclusion Criteria:\n\n* Pathologically confirmed R\u002FM SGC patients\n* Tumor tissues available for organoid culture\n* ECOG score: 0-2 points\n* Life expectancy \\> 3 months\n* Normal major organ function, tolerable to chemotherapy, targeted therapy, immunotherapy: a. Hematology examination criteria must meet: WBC≥4.0×109\u002FL, ANC≥1.5×109\u002FL, PLT≥80×109\u002FL, Hb≥90 g\u002FL (no blood transfusion or blood products within 14 days, no use of G-CSF or other hematopoietic growth factors); b. Biochemical examination must meet the following criteria: serum albumin≥3.0 g\u002FdL (30 g\u002FL), TBIL≤1.5×ULN, ALT, AST≤2.5×ULN, BUN and CRE≤1.5×ULN or endogenous creatinine clearance≥60 ml\u002Fmin (Cockcroft-Gault formula); c. Good coagulation function: defined as International Normalized Ratio (INR) or Prothrombin Time (PT)≤1.5 times ULN; if the study participant is on anticoagulant therapy, as long as PT is within the intended range of the anticoagulant medication\n* Able to understand the content of informed consent form, sign the informed consent form, and willing to cooperate with the follow-up\n\nExclusion Criteria:\n\n* Metastatic tumors in the head and neck region, or non-salivary gland cancer tumors such as sarcoma, squamous cell carcinoma, nasopharyngeal carcinoma, etc.\n* Known allergy to the study drugs or their active ingredients or any excipients; or had a severe allergic reaction to other monoclonal antibodies\n* Pregnant or breastfeeding female patients; or women of childbearing age with positive pregnancy test results (serum or urine) within 7 days before enrollment, or negative results but refusing to use effective contraception during the study period and 2 months after the last administration of study medication; or male patients with partners of childbearing age, refusing to use effective contraception during the study period and 2 months after the last administration of study medication\n* Severe liver diseases (such as cirrhosis), kidney diseases, respiratory system diseases, hematopoietic system diseases, or endocrine system diseases, uncontrolled diseases\n* Infected with HIV, active hepatitis B (HBV-DNA≥104 copies\u002Fml) or hepatitis C (hepatitis C antibody positive, and HCR-RNA above the lower limit of detection of the analytical method), uncontrolled diseases\n* Within 6 months before enrollment, the following conditions occurred: myocardial infarction, severe\u002Funstable angina, NYHA class 2 or above heart failure, clinically significant supraventricular or ventricular arrhythmias, and symptomatic congestive heart failure, uncontrolled diseases\n* Patients with mental illness or known history of psychiatric drug abuse or drug addiction\n* Unable to give consent, unable to obtain the required amount of tumor tissue for the study\n* Other serious physical or mental diseases or laboratory test abnormalities that may increase the risk of participating in the study or interfere with the study results; or any other situation that the researchers deem unsuitable for participation in this study","ALL","18 Years","80 Years",{"count":19,"type":20},40,"ESTIMATED","2 Years","OBSERVATIONAL","To evaluate the consistency of drug efficacy between the clinical systemic treatment and drug sensitive test based on patient-derived organoid in R\u002FM SGC patients, using a prospective and multicenter observational study to increase the generalizability and reliability of research conclusion.",[25,26,27],"Salivary Gland Cancers","Patient Derived Organoid","Drug Sensitive Test in Vitro",[29,30,31],"Recurrent\u002Fmetastatic salivary gland cancer","Patient-derived organoid","Drug sensitive test in vitro","RECRUITING","2025-08-26",{"date":35,"type":36},"2025-09-03","ACTUAL",{"date":38,"type":36},"2025-03-26",{"date":40,"type":20},"2028-11-30",{"name":42,"class":43},"Huashan Hospital","OTHER",{"id":45,"slug":4,"hasResults":10,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":50,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":59,"leadSponsor":61,"locationsCount":5},"100568831","NCT06686342","PDO Based Drug Sensitive Test in R\u002FM HNSCC","Consistency Evaluation of Drug Efficacy Between Clinical Systemic Treatment and Drug Sensitive Test Based on Patient-derived Organoid in Patients With Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma: A Prospective, Multicenter, Observational Study","Inclusion Criteria:\n\n* Pathologically confirmed R\u002FM HNSCC patients\n* Tumor tissues available for organoid culture\n* ECOG score: 0-2 points\n* Life expectancy \\> 3 months\n* Normal major organ function, tolerable to chemotherapy, targeted therapy, immunotherapy: a. Hematology examination criteria must meet: WBC≥4.0×109\u002FL, ANC≥1.5×109\u002FL, PLT≥80×109\u002FL, Hb≥90 g\u002FL (no blood transfusion or blood products within 14 days, no use of G-CSF or other hematopoietic growth factors); b. Biochemical examination must meet the following criteria: serum albumin≥3.0 g\u002FdL (30 g\u002FL), TBIL≤1.5×ULN, ALT, AST≤2.5×ULN, BUN and CRE≤1.5×ULN or endogenous creatinine clearance≥60 ml\u002Fmin (Cockcroft-Gault formula); c. Good coagulation function: defined as International Normalized Ratio (INR) or Prothrombin Time (PT)≤1.5 times ULN; if the study participant is on anticoagulant therapy, as long as PT is within the intended range of the anticoagulant medication\n* Able to understand the content of informed consent form, sign the informed consent form, and willing to cooperate with the follow-up\n\nExclusion Criteria:\n\n* Metastatic tumors in the head and neck region, or non-HNSCC such as sarcoma, adenocarcinoma, nasopharyngeal carcinoma, etc.\n* Known allergy to the study drugs or their active ingredients or any excipients; or had a severe allergic reaction to other monoclonal antibodies\n* Pregnant or breastfeeding female patients; or women of childbearing age with positive pregnancy test results (serum or urine) within 7 days before enrollment, or negative results but refusing to use effective contraception during the study period and 2 months after the last administration of study medication; or male patients with partners of childbearing age, refusing to use effective contraception during the study period and 2 months after the last administration of study medication\n* Severe liver diseases (such as cirrhosis), kidney diseases, respiratory system diseases, hematopoietic system diseases, or endocrine system diseases, uncontrolled diseases\n* Infected with HIV, active hepatitis B (HBV-DNA≥104 copies\u002Fml) or hepatitis C (hepatitis C antibody positive, and HCR-RNA above the lower limit of detection of the analytical method), uncontrolled diseases\n* Within 6 months before enrollment, the following conditions occurred: myocardial infarction, severe\u002Funstable angina, NYHA class 2 or above heart failure, clinically significant supraventricular or ventricular arrhythmias, and symptomatic congestive heart failure, uncontrolled diseases\n* Patients with mental illness or known history of psychiatric drug abuse or drug addiction\n* Unable to give consent, unable to obtain the required amount of tumor tissue for the study\n* Other serious physical or mental diseases or laboratory test abnormalities that may increase the risk of participating in the study or interfere with the study results; or any other situation that the researchers deem unsuitable for participation in this study",{"count":51,"type":20},100,"To evaluate the consistency of drug efficacy between the clinical systemic treatment and drug sensitive test based on patient-derived organoid in R\u002FM HNSCC patients, using a prospective and multicenter observational study to increase the generalizability and reliability of research conclusion.",[54,26,27],"Head and Neck Squamous Cell Carcinoma",[56,30,31],"Recurrent\u002Fmetastatic head and neck squamous cell carcinoma",{"date":35,"type":36},{"date":38,"type":36},{"date":60,"type":20},"2028-11-11",{"name":42,"class":43},""]